natgillin/translations-raw huggingface dataset:
1st injection: from 1 month of age in naive animals (or from 2.5 months of age in young cattle and sheep born to immune animals).
Prvi odmerek: od 1 meseca starosti pri predhodno necepljenih živalih (ali od 2,5 meseca starosti pri potomcih imunih krav in ovc).
1st occurrence of any grade 2 or 3 AE
1. pojav katerega koli neželenega dogodka stopnje 2 ali 3
1st occurrence of any grade 4 AE
1. pojav katerega koli neželenega dogodka stopnje 4
1st occurrence: 40 mg
1. pojav: 40 mg
1st scheme – vaccination against equine influenza:
Shema 1 – cepljenje proti influenci konj:
1st treatment
prva infuzija
1st year
1. leto
1st year of life
1. leto življenja
1st, 2nd or booster) were similar and are listed according to the following frequency:
1., 2. ali obnovitvenem) so bile podobne in so naštete v skladu z naslednjo pogostnostjo:
1The correlation between macrolide MICs and clinical outcome is weak for H. influenzae.
1Pri H. influenzae je korelacija med MIC makrolidov in kliničnim izidom šibka.
1Up-titration of insulin regimens (including short-acting, intermediate, and basal insulin) was only allowed if subjects met pre-defined FPG criteria.
1Zviševanje insulinskih shem (vključno s kratkodelujočim, srednjedolgodelujočim in bazalnim insulinom) je bilo dovoljeno le, če so bolniki izpolnjevali vnaprej določena merila glukoze v plazmi na tešče.
1vial
1 viala
1x 500 doses
1x 500 odmerkov
1x20 ml solution for infusion 200 mg/20 ml
1x20 ml raztopine za infundiranje 200 mg/20 ml
1x30 tablets
1x30 tablet
1x50 tablets
1x50 tablet
1½ inch, 22 gauge (0.72 mm x 38.1 mm) needle regardless of body weight.
1½ palca in velikosti 22G (0,72 mm x 38,1 mm) ne glede na bolnikovo telesno maso.
1ère Avenue - 2065 m 06516 Carros, France
L.I.D. 1ère Avenue - 2065 m 06516 Carros, France
1ère Avenue - 2065 m – L.I.D 06516 Carros, France
1ère Avenue - 2065 m – L.I.D 06516 Carros, Francija
1ère Avenue 2065m L.I.D. 06516 Carros - France
1ère Avenue 2065m L.I.D. 06516 Carros – Francija
1ère avenue – 2065 m – L.I.D., 06516 Carros Cedex
1ère avenue – 2065 m – L.I.D., 06516 Carros Cedex, Francija
1“Somnolence” term includes: somnolence and sedation.
1 Izraz »zaspanost« vključuje: zaspanost in sedacijo.
2 % of subjects with titre ≥1:28
2% preiskovancev s titri ≥1:28
2 % of subjects with titres ≥1:28
2% preiskovancev s titri ≥1:28
2 (0.2)
občasni
2 (2 x 1) vials (multipack)
2 (2 x 1) viali (multiplo pakiranje)
2 (automatic day 14 increase)
2 (avtomatsko povišanje odmerka 14 dan)
2 (automatic day 14 increase)
2 (avtomatsko povišanje odmerka 14. dan)
2 1000 mg on Day 1 + 500 mg on Day 8; Study DUR001-303 subjects with evaluable PK sample.
1000 mg 1. dan + 500 mg 8. dan; študija DUR001-303 oseb z ovrednotenim PK vzorcem.
2 4-fold increase in serum neutralising antibody titre
2 4-kratno povečanje serumskih titrov nevtralizirajočih protiteles
2 additional adverse reaction observed with brinzolamide monotherapy
2 dodatni neželeni učinek, ki so ga opazili pri monoterapiji z brinzolamidom
2 additional adverse reactions observed with timolol monotherapy
2 dodatni neželeni učinki, ki so jih opazili pri monoterapiji s timololom
2 Administration every 3 to 4
2 aplikacija vsake 3 do 4 tedne
2 Administration every 3 to 4 week
2 aplikacija vsake 3 do 4 tedne
2 ADRs derived only during post-marketing
2 neželeni učinki, o katerih so poročali samo v obdobju trženja
2 adsorbed on AlPO4 0.32 milligrams Al3+
2adsorbiran na AlPO4 0,32 miligramov Al3+
2 adsorbed on aluminium hydroxide (0.5 mg Al³+)
2 adsorbirano na aluminijev hidroksid (0,5 mg Al³+)
2 adsorbed on aluminium hydroxide, hydrated (approximately 0.25 milligrams Al3+)
2 adsorbirano na aluminijev hidroksid hidrat (približno 0,25 miligramov Al3+)
2 adsorbed on aluminium hydroxide, hydrated (approximately 0.25 milligrams Al3+)
2 adsorbirano na aluminijev hidroksid hidrat (približno 0,25 milligramov Al3+)
2 adsorbed on aluminium phosphate 0.37 mg Al3+ 3 produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology
2 Adsorbiran na aluminijev fosfat 0,37 mg Al3+ 3 Pridobljen s tehnologijo rekombinantne DNA na celični kulturi kvasovk (Saccharomyces cerevisiae)
2 Adsorbed on aluminium phosphate 0.37 milligrams Al3+
2 Adsorbiran na aluminijev fosfat 0,37 miligrama Al3+
2 adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.15 mg Al3+)
2 adsorbiran na amorfni aluminijev hidroksifosfat sulfat (0,15 mg Al3+)
2 Adverse reaction observed with Ultibro Breezhaler and at least one of the individual components.
2 neželeni učinek, ki so ga opažali pri uporabi zdravila Ultibro Breezhaler in pri vsaj eni od posameznih sestavin
2 Adverse reaction observed with Ulunar Breezhaler and at least one of the individual components.
2 neželeni učinek, ki so ga opažali pri uporabi zdravila Ulunar Breezhaler in pri vsaj eni od posameznih sestavin
2 Adverse reaction observed with Xoterna Breezhaler and at least one of the individual components.
2 neželeni učinek, ki so ga opažali pri uporabi zdravila Xoterna Breezhaler in pri vsaj eni od posameznih sestavin
2 Adverse reactions observed with Brimica Genuair and reported in the SmPC of at least one of the individual components
2 Neželeni učinki, ki so jih opažali pri uporabi zdravila Brimica Genuair in so bili omenjeni v Povzetku glavnih značilnosti zdravila vsaj ene posamezne učinkovine.
2 Adverse reactions observed with Duaklir Genuair and reported in the SmPC of at least one of the individual components
2 Neželeni učinki, ki so jih opažali pri uporabi zdravila Duaklir Genuair in so bili omenjeni v Povzetku glavnih značilnosti zdravila vsaj ene posamezne učinkovine.
2 alcohol swabs
2 alkoholna tampona
2 Alcohol swabs
2 alkoholna zloženca
2 alcohol swabs for single use
2 einnota sprittþurrkum
2 alcohol swabs to clean the skin and vial.
2 alkoholni blazinici za čiščenje kože in vial.
2 alcohol wipes
2 alkoholna zloženca
2 alcohol wipes.
2 alkoholna zloženca
2 All randomised patients for whom data for complete wound closure were available.
2 Vsi randomizirani bolniki, za katere so bili na voljo podatki o popolnem zaprtju ran.
2 aluminium
2 alu/PVC
2 Anaemia was common and skin discolouration (increased pigmentation) was very common when emtricitabine was administered to paediatric patients.
2 Je bila pogosta anemija in zelo pogosta sprememba obarvanosti kože (povečana pigmentacija) pri pediatričnih bolnikih ob jemanju emtricitabina.
2 Angiomyolipoma responses were confirmed with a repeat scan.
2 Odzivi angiomiolipoma so bili potrjeni s ponovnim slikanjem.
2 As lower confidence limit (p= 0.95)
2 Kot spodnja meja zaupanja (p = 0,95).
2 Autoclicks pre-filled pen + 2 alcohol wipes
2 napolnjena injekcijska peresnika Autocliks + 2 alkoholna zloženca
2 Based on a Log-rank test.
2 Na podlagi testa log-rank.
2 Bendamustine is given intravenously on Days 1 and 2 of all treatment cycles (Cycles 1-6) at 90 mg/m2/day
2 Bendamustin dajemo intravensko na 1. in 2. dan vseh ciklusov zdravljenja (1. do 6. ciklus) v odmerku 90 mg/m2/dan
2 blister cards of 3 pipettes
2 blistra s 3 pipetami
2 blisters of 10 tablets
2 pretisni od 10 tablete
2 bottles of 1 ml
2 steklenički po 1 ml
2 bottles of 180 tablets with outer carton
2 steklenici s po 180 tabletami z zunanjo ovojnino
2 bottles of 360 tablets with outer carton
2 steklenici s po 360 tabletami z zunanjo ovojnino
2 capsules in the morning and 2 capsules in the evening
2 kapsuli zjutraj in 2 kapsuli zvečer
2 cartridges of 3 mL.
2 vložka po 3 ml.
2 clean glasses
2 čista kozarca
2 cleansing swabs;
2 čistilna tampona;
2 Common in dialysis
2 Pogosto pri dializi
2 conjugated to tetanus toxoid carrier protein 5-10 micrograms
2 konjugiran na nosilno beljakovino tetanusnega toksoida 5–10 mikrogramov
2 CR=complete response; PR=partial response
2 CR = popoln odziv; PR = delni odziv
2 Cytogenetic response criteria:
2Kriteriji citogenetičnega odziva:
2 D-78467 Konstanz Germany
2 D-78467 Konstanz Nemčija
2 Derived values are presented.
2 Predstavljene so izpeljane vrednosti.
2 Dose recommendations are based on pharmacokinetic modelling
2 Priporočila za odmerjanje temeljijo na farmakokinetičnem modeliranju.
2 dose steps selected
izbrana 2 odmerna koraka
2 doses
odmerek
2 doses (week 0 and week 4)
2 odmerka (teden 0 in 4)
2 doses (week 0 and week 4)
2 odmerka (v tednu 0 in 4)
2 doses 2 weeks apart with a booster dose 1 year later
2 odmerka 2 tedna narazen s poživitvenim odmerkom po 1 letu
2 doses 7-11 days apart
2 odmerka 7-11 dni narazen
2 doses of IMVANEX
2 odmerka cepiva IMVANEX
2 dosing syringes (5 ml) – which are to be used more than once
2 odmerni brizgi (5 ml) – namenjeni sta za večkratno uporabo
2 drinking straws
dve slamici.
2 e.g.
2 Npr.
2 egg infective dose 50%.
2 50% infektivni odmerek za embrionirana kokošja jajca
2 Estimated median survival
2 ocenjeno mediano preživetje
2 EUCAST has not determined non-species related breakpoints for anidulafungin
2 Odbor EUCAST ni določil mejnih vrednosti za anidulafungin, neodvisnih od vrste.
2 Excludes asthenia and anorexia; asthenia and Grade 3 anorexia do not require dose adjustment.
2 Brez astenije in anoreksije; pri asteniji in anoreksiji 3. stopnje odmerka ni treba prilagoditi.
2 Fatalities due to sepsis have been reported in patients treated with topotecan (see section 4.4)
2 Pri bolnikih, ki so se zdravili s topotekanom, so poročali o smrti zaradi sepse (glejte poglavje 4.4).
2 Fatalities due to sepsis have been reported in patients treated with topotecan (see section 4.4).
2 Pri bolnikih, ki so se zdravili s topotekanom, so poročali o smrti zaradi sepse (glejte poglavje 4.4).
2 film-coated tablets 4 film-coated tablets 8 film-coated tablets
2 filmsko obloženi tableti 4 filmsko obložene tablete 8 filmsko obloženih tablet
2 film-coated tablets 4 film-coated tablets 8 film-coated tablets 12 film-coated-tablets
2 filmsko obloženi tableti 4 filmsko obložene tablete 8 filmsko obloženih tablet 12 filmsko obloženih tablet
2 filter transfer devices
2 pripravi za prenos s filtrom,
2 filter transfer devices, 1 disposable 10 ml syringe, 1 venipuncture set, and 1 protective mat.
2 pripravi za prenos s filtrom, 1 10-mililitrsko brizgo za enkratno uporabo, 1 komplet za punkcijo vene in 1 zaščitno podlogo.
2 Flocculation equivalents; corresponds with ≥ 30 IU/ml guinea pig serum in the Ph.Eur. potency test
2 flokulacijski ekvivalenti; ustreza ≥30 i.e/ml seruma budre v preizkusu potentnosti v Ph.Eur.
2 Fluid collection includes localised oedema, pseudocyst and implant site effusion.
2 Kopičenje tekočine vključuje lokaliziran edem, psevdocisto in izliv na mestu vsaditve.
2 Follow-up analysis was performed with a data cut-off date of 07 March 2014; all p-values are displayed for descriptive purpose only
2 Analizo po spremljanju so opravili s podatki, zajetimi do 7. marca 2014; vse vrednosti p so napisane samo za deskriptivne namene.
2 For all efficacy endpoints the confidence intervals were 95%, except for HIV-1 RNA Change from baseline which was 97.5%
2 Intervali zaupanja so bili za vse primarne cilje učinkovitosti 95 %, za spremembo HIV-1 RNA od izhodišča pa 97,5 %.
2 For further description, please see sub-section “Description of selected adverse reactions”
2 Za podrobnejši opis glejte podpoglavje »Opis izbranih neželenih učinkov«
2 full turns (10 clicks)
polna obrata (10 klikov)
2 g NexoBrid powder in 20 g gel is applied to a burn wound area of 100 cm2.
Zdravilo 2 g NexoBrid prašek in 20 g gel se nanese na predel opeklinske rane površine 100 cm2.
2 g powder in a vial (glass type II) sealed with a rubber (bromobutyl), stopper and covered with a cap (aluminium), and 20 g gel in a bottle (borosilicate, glass type I), sealed with a rubber stopper and covered with a screw cap (tamper-proof polypropylene).
g praška v viali (steklo tipa II), zamašeni z gumijastim (bromobutilnim) zamaškom, prekriti z zaporko (aluminij), in 20 g gela v steklenički (borosilikat iz stekla tipa I), zamašeni z gumijastim zamaškom in prekriti z varnostno navojno zaporko (polipropilen, ki se poškoduje ob odpiranju).
2 g/kg
1,6–2 g/kg
2 Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite occur most frequently during initiation of therapy and resolve spontaneously in most cases.
2 Gastrointestinalni simptomi, npr. navzea, bruhanje, driska, bolečine v trebuhu in izguba apetita, se najpogosteje pojavijo med uvedbo zdravljenja in večinoma spontano minejo.
2 Histological response defined as a ≥ 2 point decrease in Knodell Necroinflammatory Score from baseline with no worsening of the Knodell Fibrosis Score.
2 histološki odziv opredeljen kot znižanje od izhodišča za ≥2 točki na Knodellovi nekroinflamatorni lestvici (Knodell Necroinflammatory Score) brez sočasnega poslabšanja na Knodellovi fibrozni lestvici (Knodell Fibrosis Score)
2 hours after boosted PREZISTA
pred ali 2 uri po odmerjanju
2 hours after omeprazole)
2 uri po omeprazolu)
2 hours after raltegravir
2 uri po raltegravirju
2 hours before raltegravir raltegravir AUC  51 % raltegravir C12 hr  56 %
2 uri pred raltegravirjem AUC raltegravirja  51 % C12ur raltegravirja  56 % Cmax raltegravirja  51
2 hours before raltegravir raltegravir AUC  51 % raltegravir C12 hr  56 %
2 uri pred raltegravirjem raltegravir AUC  51 % raltegravir C12ur  56 % raltegravir Cmax  51
2 hr
2 h
2 HR 95% CI p-value (Z) vs (P) 0.83 (0.76, 0.90) <.001
2 HR 95 % IZ p-vrednost (Z) vs (P) 0,83 (0,76, 0,90) < 0,001
2 Identified adverse reactions of empagliflozin monotherapy
2 Neželeni učinki, o katerih so poročali pri empagliflozinu v monoterapiji.
2 Immunosuppressant therapy could only be discontinued at or after Week 26 at the investigator's discretion if the subject met the clinical response criterion
2Zdravljenje z imunosupresivi je bilo lahko prekinjeno v 26. tednu ali po njem po raziskovalčevi diskreciji, če je bolnik izpolnjeval kriterije kliničnega odziva.
2 Immunosuppressant therapy could only be discontinued at or after Week 26 at the investigator's discretion if the subject met the clinical response criterion
2Zdravljenje z imunosupresivi je bilo lahko prekinjeno v 26.tednu ali po njem po raziskovalčevi diskreciji, če je bolnik izpolnjeval kriterije kliničnega odziva.
2 implants
2 implantata
2 implants preloaded in implanters + 1 actuator
2 implantata, napolnjena v implantatorja + 1 aktuator
2 In a pooled analysis of 20 placebo-controlled studies with duration greater than 2 weeks up to 1 year in patients with OA and RA, the excess rate of myocardial infarction in patients treated with celecoxib 200 or 400 mg daily over placebo was 0.7 events per 1000 patients (Rare) and there was no excess of strokes.
2 V kumulativni analizi 20 s placebom kontroliranih študij pri bolnikih z OA in RA, ki so trajale več kot 2 tedna in do 1 leta, je bil presežni delež miokardnega infarkta pri bolnikih, ki so dobivali 200 mg ali 400 mg celekoksiba na dan, v primerjavi s placebom 0,7 dogodka na 1000 bolnikov (redko).
2 In a pooled analysis of 20 placebo-controlled studies with duration greater than 2 weeks up to 1 year in patients with OA and RA, the excess rate of myocardial infarction in patients treated with celecoxib 200 or 400 mg daily over placebo was 0.7 events per 1000 patients (Rare) and there was no excess of strokes. or the polyp prevention trials (Table 2).
2 V kumulativni analizi 20 s placebom kontroliranih študij pri bolnikih z OA in RA, ki so trajale več kot 2 tedna in do 1 leta, je bil presežni delež miokardnega infarkta pri bolnikih, ki so dobivali 200 mg ali 400 mg celekoksiba na dan, v primerjavi s placebom 0,7 dogodka na 1000 bolnikov (redko).
2 In clinical studies, response to voriconazole in patients with C. glabrata infections was 21% lower compared to C. albicans, C. parapsilosis and C. tropicalis.
2 V kliničnih študijah je bil odziv na vorikonazol pri bolnikih z okužbami s C. glabrata za 21 % manjši kot pri C. albicans, C. parapsilosis in C. tropicalis.
2 In countries where the 7.5 mg capsule is available.
2 V državah, kjer je na voljo 7,5 mg kapsula.
2 In insulin-comparator controlled studies in which metformin and a sulphonylurea were concomitant medicinal products, the incidence for these adverse reactions was similar for insulin- and immediate-release exenatide-treated patients.
2 V z insulinom primerjalnih nadzorovanih študijah, v katerih so bolniki sočasno dobivali metformin in sulfonilsečnino, je bila incidenca teh neželenih učinkov podobna za bolnike zdravljene z insulinom in zdravilom BYETTA.
2 in patients randomised to Humalog Mix25 during the first crossover period
2pri naključnih bolnikih, ki so prejemali zdravilo Humalog Mix25 med prvim obdobjem navzkrižnosti
2 in patients randomised to Liprolog Mix25 during the first crossover period
2pri naključnih bolnikih, ki so prejemali zdravilo Liprolog Mix25 med prvim obdobjem navzkrižnosti
2 In some cases of myopathy involving raised CPK and muscle symptoms, the patients also presented with elevated transaminases.
2 Pri nekaterih bolnikih z miopatijo z zvišano vrednostjo kreatin-fosfokinaze in mišičnimi simptomi so zabeležili tudi zvišane vrednosti aminotransferaz.
2 In the photoactivated area
2 v fotoaktiviranem predelu
2 Includes events occurring after first dose of apixaban (post-surgery)
2 Vključuje dogodke po prvem odmerku apiksabana (po operaciji).
2 Includes immune thrombocytopenic purura.
2 Vključuje imunsko trombocitopenično purpuro.
2 Includes Stomatitis, Aphthous stomatitis, Mucosal inflammation, Mouth ulceration, Oral mucosa erosion, Mucosal erosion, Mucosal ulceration
2 zajema stomatitis, aftozni stomatitis, vnetje sluznice, ulceracijo v ustni votlini, erozijo ustne sluznice, erozijo sluznice, ulceracije sluznice
2 Including in-growing eyelashes, excessive growth and thickening of the eyelashes.
2 Vključno z vraščenimi trepalnicami, povečano rastjo in odebelitvijo trepalnic.
2 inhalers (2x120 doses)
2 inhalatorja (2x120 odmerkov)
2 inhalers (2x60 doses)
2 inhalatorja (2x60 odmerkov)
2 inner cartons).
2 notranji škatli).
2 International units of beta antitoxin according to Ph.
2 Internacionalne enote beta antitoksina po Ph.
2 Investigator assessed PFS analysis with data cut-off date of 30 November 2010.
2 Analiza podatkov preživetja brez napredovanja bolezni, ocenjenih s strani raziskovalca, zbranih do 30. novembra 2010.
2 Isolated cases reported in post-marketing experience
2Osamljeni primeri, o katerih so poročali v okviru postmarketinških izkušenj.
2 Isolated cases reported in post-marketing experience.
2Osamljeni primeri, o katerih so poročali v okviru izkušenj v obdobju trženja.
2 Isolated cases reported in post-marketing experience.
2Osamljeni primeri, o katerih so poročali v okviru postmarketinških izkušenj.
2 IU
2 i.e.
2 IU International Unit
2 i.e. internacionalna enota.
2 kg/tonne*
2 kg/tono
2 Laguno M, Murillas J, Blanco J.L et al.
2 Laguno M, Murillas J, Blanco J.L in sod.
2 Laguno M, Murillas J, Blanco J.L et al.
2Laguno M, Murillas J, Blanco J.L in sod.
2 level reduction (mcg)
Drugo zmanjšanje odmerka (mikrogrami)
2 litre aluminium gas cylinder 10 litre aluminium gas cylinder
2-litrska aluminijasta jeklenka 10-litrska aluminijasta jeklenka
2 litres gas cylinder
2–litrska jeklenka
2 litres of liquid per day).
2 litra tekočine na dan).
2 Lowest concentration, which completely inhibits visible growth of at least 90 % of isolates
2 Najnižja koncentracija, ki povsem inhibira vidno rast najmanj 90 % izolatov
2 matrices of 4.8 x 4.8 cm
2 matriksa 4,8 x 4,8 cm
2 Mean adjusted for baseline HbA1c, baseline eGFR, geographical region and number of antihypertensive medicinal products
2 Povprečje, prilagojeno za vrednost HbA1c ob izhodišču, vrednost eGFR ob izhodišču, geografsko regijo in število antihipertenzivnih zdravil
2 Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline.
2Povprečno povečanje vrednosti lipidov na tešče (skupni holesterol, holesterol LDL in trigliceridi) je bilo večje pri bolnikih, pri katerih v izhodišču ni bila dokazana motnja v delovanju lipidov.
2 mg (100 KIU)
2 mg (100 k.i.e.)
2 mg (2 ml of concentrate for solution for infusion)
raztopino za infundiranje)
2 mg (N = 103)
(N = 103)
2 mg (N= 114)
(N = 114)
2 mg capsule shell contains gelatin, titanium dioxide (E171), indigotine (E132), yellow iron oxide (E172), erythrosin (E127) and white ink.
Ovojnica 2 mg kapsule vsebuje: želatino, titanov dioksid (E171), indigotin (E132), rumeni železov oksid (E172), eritrozin (E127) in belo črnilo.
2 mg capsule shell contains: white ink – shellac, titanium dioxide (E171), simethicone, propylene glycol (E1520) and ammonium hydroxide (E527).
Ovojnica 2 mg kapsule vsebuje: belo črnilo – šelak, titanov dioksid (E171), simetikon, propilenglikol (E1520) in amonijev hidroksid (E527).
2 mg per meal
2 mg na obrok
2 mg Q8 A
2 mg Q8A
2 mg single dose4
Enkraten odmerek 2 mg 4
2 mg single dose4
ombitasvir/p
2 mg tablet: Ferric Oxide, Yellow (E172), Ferric Oxide, Red (E172) 4 mg tablet: Ferric Oxide, Red (E172)
2 mg tableta: železov oksid, rumeni (E172), železov oksid, rdeči (E172) 4 mg tableta: železov oksid, rdeči (E172)
2 mg tablet: pale orange, round, biconvex tablets of 6 mm, marked with the Bayer cross on one side and 2 and an “R” on the other side.
2 mg tableta: svetloranžne, okrogle, bikonveksne tablete velikosti 6 mm, na eni strani označene z oznako Bayer in na drugi strani z oznakama 2 in "R".
2 mg, 5 mg, 10 mg and 20 mg hard capsules: Apotek Produktion & Laboratorier AB Prismavägen 2
2 mg, 5 mg, 10 mg in 20 mg trde kapsule: Apotek Produktion & Laboratorier AB Primasvägen 2
2 mg/kg for patients with body weight of 15 kg or more, up to a maximum of 40 kg
2 mg/kg za bolnike s telesno maso najmanj 15 kg in največ 40 kg
2 mg/kg for patients with body weight ≥ 15 kg and ≤ 40 kg
2 mg/kg za bolnike s telesno maso ≥ 15 kg in ≤ 40 kg
2 mg/kg twice daily and 4 mg/kg twice daily, respectively).
3,577 ng·h/ml pri 2 mg/kg dvakrat dnevno in 3,371 ng·h/ml pri 4 mg/kg dvakrat dnevno).
2 mg/kg/day*
2 mg/kg/dan
2 mg/ml : 3.45 mg/ml (0.150 mmol/ml) sodium
2 mg/ml: 3,45 mg/ml (0,150 mmol/ml) natrija
2 minutes, e.g. in haemodialysis patients via the arterio-venous fistula at the end of dialysis.
Intravensko moramo zdravilo vbrizgavati približno 2 minuti, hemodializnim bolnikom pa npr. skozi arteriovensko fistulo ob koncu dializnega postopka.
2 mixing cups with joined lids – which are to be used more than once
2 posodici za mešanje s pritrjenim pokrovom – namenjeni sta za večkratno uporabo
2 ml (40 mg) twice daily
2 ml (40 mg) dvakrat na dan
2 ml = 1 dose 10 d 20 ml vial
2 ml= 1 odmerek, 10 odmerkov 20 ml steklena viala.
2 ml = 1 dose 25 d 50 ml vial
2 ml = 1 odmerek, 25 odmerkov 50 ml steklena viala.
2 ml = 1 dose 5d 10 ml vial
2 ml =1 odmerek, 5 odmerkov 10 ml steklena viala.
2 ml ampoule: colourless neutral glass, Type I.
2 ml ampula: brezbarvno naravno steklo, tip I.
2 ml ampoules for the use with Venta-Neb:
2 ml ampule za uporabo z nebulatorjem Venta-Neb:
2 ml contains:
En odmerek po 2 ml vsebuje:
2 ml glass ampoules
2 ml steklene ampule
2 ml of sodium acetate solution 10 ml of formulation buffer Empty reaction vial (10 ml)
2 ml raztopine natrijevega acetata 10 ml pufra za pripravo formulacije Prazna reakcijska viala (10 ml)
2 ml syringe) and needle (e.g.
2-mililitrsko injekcijsko brizgo) in iglo (npr.
2 ml syringe) and needle (e.g.
2-mililitrsko) in iglo (npr.
2 ml syringe) and needle (e.g.
2-mililitrsko) ter iglo (npr.
2 ml vial (Type I glass) with a stopper (butyl rubber) and a seal (aluminium) with a flip-off cap (polypropylene).
2-mililitrska viala (steklo tipa I) z zamaškom (butilna guma) in tesnilom (aluminij) z dvižno zaporko (polipropilen).
2 mL vial: EU/1/16/1105/001
2 ml viala: EU/1/16/1105/001
2 ml, by subcutaneous injection (injection given under the skin).
2 ml, subkutana injekcija (injekcija dana pod kožo).
2 mL/pre-filled syringe
2 ml/napolnjeno injekcijsko brizgo
2 months to <3 years
2 meseca do < 3 leta
2 months –
2 meseca
2 N: number of subjects with evaluable pharmacokinetic results
2N: število oseb s farmakokinetičnimi rezultati, ki jih je mogoče oceniti
2 needles
2 igli.
2 not evaluated for statistical significance as a part of the sequential confirmatory testing procedure
2 Statistična značilnost ni bila ocenjena zaradi zaporednega potrditvenega postopka testiranja